# Enterome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enterome

- Industry: Pharmaceuticals
- Headquarters: Paris, France
- Website: www.enterome.com
- Total disclosed funding: $67M
- Latest round: Series E (Oct 23, 2020)
- Investors on record: 8

## About

Enterome SA is a clinical-stage biotechnology company focused on developing innovative immunotherapy solutions to combat cancer through its proprietary OncoMimics™ platform, enhancing the body’s immune response against tumors.Founded in 2011 and headquartered in Paris, France, Enterome SA specializes in immunotherapy for cancer treatment. The company has executed a total of 8 deals, with its most recent funding round being a Series E of EUR 30.00 mn on October 23, 2020, involving investors such as Nestle Health Science SA and Takeda Pharmaceutical Company Limited. Pierre Belichard leads the company as CEO.Enterome is engaged in developing innovative immunotherapy treatments targeting various cancer types, including glioblastoma, adrenal tumors, non-Hodgkin lymphoma, and colorectal cancer. Their OncoMimics™ platform leverages patient effector memory T cells to generate robust immune responses against tumors. Key clinical programs like EO2463, EO4010, and EO2401 demonstrate promising efficacy and safety in Phase 2 trials, focusing primarily on markets in Europe and North America.In the most recent fiscal year 2024, Enterome reported a revenue of EUR 16,783,135.90 with an EBITDA of EUR -10,599,814.80. The company’s revenue model is based on partnerships and collaborations, specifically with pharmaceutical firms and research institutions, integrating their immunotherapy solutions into oncology practices through B2B transactions.Enterome plans to utilize the EUR 30.00 mn raised in its Series E funding to further advance the clinical trials of its lead product EO2401. The company aims to expand its market presence in Europe and North America, with specific plans to introduce new immunotherapy products designed to enhance treatment efficacy. The recent funding will support these initiatives, ensuring that Enterome can progress its innovative solutions in the oncology sector.

## Funding rounds

- Series E, Oct 23, 2020, $36M — Seventure Partners, Omnes Capital, Xyence Capital, Takeda Pharmaceutical Company Limited, Nestle Health Science SA, SymBiosis LLC
- Series C, Apr 20, 2016, $16M — Seventure Partners, Lundbeckfond Ventures, Nestle Health Science SA
- Series B, May 1, 2014, $15M — Seventure Partners, Omnes Capital, Amundi, Lundbeckfond Ventures

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series B, Series C, Series E
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series B, Series E
- Amundi (https://capitalatlas.ai/funds/amundi) — Series B
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series B, Series C
- Nestle Health Science SA — Series C, Series E
- Xyence Capital (https://capitalatlas.ai/funds/xyence-capital) — Series E
- Takeda Pharmaceutical Company Limited — Series E
- SymBiosis LLC — Series E